晚期胃癌治疗模式的进展。
Advances in Treatment Models of Advanced Gastric Cancer.
机构信息
Department of General Surgery, 198153Nanfang Hospital, 70570Southern Medical University, Guangzhou, China.
The First Clinical Medical School, 70570Southern Medical University, Guangzhou, Guangdong, China.
出版信息
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090353. doi: 10.1177/15330338221090353.
Abstract
The prognosis of advanced gastric cancer (AGC) is extremely poor, and the therapeutic effect of traditional palliative chemotherapy is far from satisfactory. To overcome this bottleneck, palliative surgery resection, perioperative chemotherapy combined with surgical resection, hyperthermic intraperitoneal chemotherapy (HIPEC), pressurized intraperitoneal aerosol chemotherapy (PIPAC), radiation therapy, molecular-targeted therapy have been explored in AGC. Although considerable progress has been achieved, there is still no overwhelming therapeutic method. Due to the high heterogeneity of AGC, it is particularly vital to reshaped the paradigm of gastric cancer therapy according to the characteristics of clinical classifications and molecular subtypes.
摘要
晚期胃癌（AGC）的预后极差，传统的姑息性化疗疗效远不能令人满意。为了克服这一瓶颈，姑息性手术切除、围手术期化疗联合手术切除、腹腔内热灌注化疗（HIPEC）、腹腔内加压气溶胶化疗（PIPAC）、放疗、分子靶向治疗等方法已在 AGC 中进行了探索。尽管取得了相当大的进展，但仍没有一种压倒性的治疗方法。由于 AGC 的高度异质性，根据临床分类和分子亚型的特点重塑胃癌治疗模式尤为重要。
相似文献
1
Advances in Treatment Models of Advanced Gastric Cancer.晚期胃癌治疗模式的进展。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090353. doi: 10.1177/15330338221090353.
2
[Progress in prophylatic hyperthermic intraperitoneal chemotherapy for advanced gastric carcinoma].[进展期胃癌预防性腹腔内热化疗的研究进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 May 25;21(5):593-599.
3
Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.多中心 III 期随机对照临床试验研究方案，旨在评估新辅助化疗（NAC）联合新辅助腹腔镜腹腔内热化疗（NLHIPEC）序贯 R0 胃切除术后术中腹腔内热化疗（HIPEC）治疗进展期胃癌（AGC）的疗效：龙 II 试验。
BMC Cancer. 2020 Mar 17;20(1):224. doi: 10.1186/s12885-020-6701-2.
4
Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.胃癌伴腹膜转移：单中心概述及不同手术和腹腔内治疗的比较。
Langenbecks Arch Surg. 2023 Nov 16;408(1):437. doi: 10.1007/s00423-023-03163-1.
5
Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study.腹腔内热灌注化疗（HIPEC）联合全身化疗对比 D2 根治术后局部进展期胃癌单纯全身化疗的随机对照研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11491-11498. doi: 10.1007/s00432-023-05019-z. Epub 2023 Jul 1.
6
Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review.腹腔内热灌注化疗治疗胃癌：一篇综述。
Int J Environ Res Public Health. 2022 Jan 7;19(2):681. doi: 10.3390/ijerph19020681.
7
Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis.腹腔内热灌注化疗对晚期胃癌生存率及复发率的影响：系统评价与荟萃分析。
Int J Surg. 2023 Aug 1;109(8):2435-2450. doi: 10.1097/JS9.0000000000000457.
8
A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer.一种新型的床边腹腔内热化疗辅助治疗 III 期胃癌的方法。
Int J Hyperthermia. 2022;39(1):239-245. doi: 10.1080/02656736.2022.2028018.
9
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].[胃癌的细胞减灭术及腹腔热灌注化疗]
Chirurg. 2021 Jun;92(6):522-527. doi: 10.1007/s00104-021-01371-3. Epub 2021 Feb 23.
10
Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.进展期胃癌预防性腹腔内热化疗的预后分析：一项倾向评分匹配分析
J Gastrointest Surg. 2023 Nov;27(11):2297-2307. doi: 10.1007/s11605-023-05823-5. Epub 2023 Sep 15.
引用本文的文献
1
Exploring ferroptosis and miRNAs: implications for cancer modulation and therapy.探索铁死亡与微小RNA：对癌症调控和治疗的意义
Mol Cell Biochem. 2025 Jan 27. doi: 10.1007/s11010-024-05169-9.
2
Therapeutic efficacy of immunotherapy for gastric cancer metastasis.免疫疗法对胃癌转移的治疗效果。
World J Gastrointest Surg. 2024 Dec 27;16(12):3881-3886. doi: 10.4240/wjgs.v16.i12.3881.
3
Cyclophilin A knockdown inhibits the proliferation and metastatic ability of AGS gastric cancer stem cells by downregulating CD147/STAT3/AKT/ERK and epithelial‑mesenchymal transition.亲环蛋白 A 敲低通过下调 CD147/STAT3/AKT/ERK 和上皮-间充质转化抑制 AGS 胃癌干细胞的增殖和转移能力。
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13379. Epub 2024 Nov 8.
4
Interleukin-6 serves as a critical factor in various cancer progression and therapy.白细胞介素-6 在多种癌症的发生和治疗中起着关键作用。
Med Oncol. 2024 Jun 20;41(7):182. doi: 10.1007/s12032-024-02422-5.
5
Identification and Validation of a Cancer-Testis Antigen-Related Signature to Predict the Prognosis in Stomach Adenocarcinoma.一种用于预测胃腺癌预后的癌-睾丸抗原相关特征的鉴定与验证
J Cancer. 2024 May 11;15(11):3596-3611. doi: 10.7150/jca.91842. eCollection 2024.
6
Evolution and Trends of Aptamers in Cancer Research: A Bibliometric Analysis of the Literature over the Last Decade.适体在癌症研究中的演变与趋势：过去十年文献的文献计量分析
Curr Med Chem. 2024 Feb 14. doi: 10.2174/0109298673280993240125091756.
7
IDF-11774 Induces Cell Cycle Arrest and Apoptosis by Inhibiting HIF-1α in Gastric Cancer.IDF-11774通过抑制胃癌中的HIF-1α诱导细胞周期停滞和凋亡。
Pharmaceutics. 2023 Dec 13;15(12):2772. doi: 10.3390/pharmaceutics15122772.
8
Novel and efficient method for culturing patient-derived gastric cancer stem cells.一种新型高效的培养患者来源胃癌干细胞的方法。
Cancer Sci. 2023 Aug;114(8):3259-3269. doi: 10.1111/cas.15840. Epub 2023 May 20.
本文引用的文献
1
International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1).IV期胃癌转化治疗的国际回顾性队列研究1（CONVO-GC-1）。
Ann Gastroenterol Surg. 2021 Oct 20;6(2):227-240. doi: 10.1002/ags3.12515. eCollection 2022 Mar.
2
Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience.糖尿病促进胃癌淋巴结转移：15 年单中心经验。
Chin Med J (Engl). 2022 Apr 20;135(8):950-961. doi: 10.1097/CM9.0000000000001795.
3
4
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.帕博利珠单抗对比紫杉醇用于治疗既往 PD-L1 阳性的晚期胃或胃食管结合部腺癌：随机 3 期 KEYNOTE-061 试验的 2 年更新结果。
Gastric Cancer. 2022 Jan;25(1):197-206. doi: 10.1007/s10120-021-01227-z. Epub 2021 Sep 1.
5
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
6
Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial.阿帕替尼联合紫杉醇/S-1治疗具有不可切除因素的晚期胃癌后转化手术的疗效：一项多中心、单臂、II期试验
Front Pharmacol. 2021 Mar 19;12:642511. doi: 10.3389/fphar.2021.642511. eCollection 2021.
7
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.FAST：一项关于zolbetuximab（IMAB362）联合EOX 对比 EOX 一线治疗晚期 CLDN18.2 阳性胃和胃食管腺癌的随机 II 期研究。
Ann Oncol. 2021 May;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19.
8
Gastric cancer: Epidemiology, risk factors and prevention strategies.胃癌：流行病学、危险因素及预防策略。
Chin J Cancer Res. 2020 Dec 31;32(6):695-704. doi: 10.21147/j.issn.1000-9604.2020.06.03.
9
Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response.手术应激促进肿瘤进展：聚焦免疫反应的影响
J Clin Med. 2020 Dec 18;9(12):4096. doi: 10.3390/jcm9124096.
10
Impact of diabetes on prognosis of gastric cancer patients performed with gastrectomy.糖尿病对接受胃切除术的胃癌患者预后的影响。
Chin J Cancer Res. 2020 Oct 31;32(5):631-644. doi: 10.21147/j.issn.1000-9604.2020.05.08.
Zotero 插件